Business context and reporting period
Danaher Corporation’s Form 10-K reports the fiscal year ended December 31, 2020, with comparisons to 2019 and 2018. It is an annual filing, not a standalone fourth-quarter report; the supplied filing text does not provide a clear set of standalone Q4 financial results. Danaher operates globally across Life Sciences, Diagnostics, and Environmental & Applied Solutions, with more than 20 operating companies and a recurring-revenue-oriented business model.
The largest strategic event was the March 31, 2020 acquisition of GE’s Biopharma business, now Cytiva, for approximately $20.7 billion in cash, net of acquired cash, plus assumed pension liabilities. Cytiva joined Life Sciences beginning in Q2. Danaher divested product lines with approximately $170 million of 2019 revenue to secure regulatory approval.
Financial performance
| Metric | FY2020 | FY2019 |
|---|---|---|
| Sales | $22.284 billion | $17.911 billion |
| Gross profit / margin | $12.475 billion / 56.0% | $9.984 billion / 55.7% |
| Operating profit / margin | $4.231 billion / 19.0% | $3.269 billion / 18.3% |
| Continuing-operations net earnings | $3.646 billion | $2.432 billion |
| Diluted EPS from continuing operations | $4.89 | $3.26 |
| Operating cash flow from continuing operations | $6.215 billion | $3.657 billion |
| Capital expenditures | $791 million | $636 million |
| Cash and cash equivalents at year-end | $6.035 billion | $19.912 billion |
| Total debt at year-end | $21.204 billion | $21.729 billion |
GAAP sales increased 24.5%; acquisitions and divestitures contributed 18.0 percentage points, while core sales growth was 6.5%. On management’s alternative basis including Cytiva, core sales growth was 9.5%. The company reported $3.510 billion of net earnings attributable to common stockholders in 2020 versus $2.940 billion in 2019; the 2019 figure included discontinued operations, so continuing-operations results provide the more direct comparison.
Segment sales and operating profit were: Life Sciences, $10.576 billion and $2.054 billion (19.4% margin); Diagnostics, $7.403 billion and $1.538 billion (20.8%); and Environmental & Applied Solutions, $4.305 billion and $979 million (22.7%). Segment sales increased 52.0% in Life Sciences and 13.0% in Diagnostics, but declined 2.0% in Environmental & Applied Solutions.
Material changes versus 2019
- Cytiva was the principal driver of reported growth, contributing 18.0 percentage points to the increase in total sales. Its core sales grew more than 30% from acquisition through year-end compared with the corresponding prior-year period.
- COVID-19-related demand supported bioprocessing, molecular diagnostics, genomics consumables, and acute-care products, while closures and deferred purchases weighed on research instruments, clinical-lab testing, microscopy, and product-identification equipment.
- Management estimated COVID-19-related demand added approximately 700–750 basis points to core sales growth including Cytiva. That demand may decline as the pandemic subsides.
- Operating margin rose 70 basis points overall. Higher volumes, productivity savings, and lower travel and business-activity spending helped; Cytiva acquisition accounting adjustments and costs offset some of those benefits. The acquisition-related inventory fair-value adjustment increased 2020 cost of sales by $457 million.
- Operating cash flow rose approximately 70%, while investing cash use increased to $21.239 billion, principally reflecting $20.971 billion of acquisition payments, primarily for Cytiva. Cash declined from $19.912 billion to $6.035 billion.
- Interest expense increased to $275 million from $108 million, primarily due to higher average debt following acquisition-related financing. The 2020 effective tax rate was 18.9%, down from 26.4% in 2019.
Outlook, risks and unusual items
Management expected core sales, both excluding and including Cytiva, to grow in Q1 2021, assuming the pandemic’s negative impact did not increase. It anticipated continued demand for COVID-19 testing, treatment, and vaccine-related products, alongside improvement in other businesses. The filing emphasizes that the pandemic’s duration and effects remained highly uncertain. Danaher forecast 2021 capital expenditures of approximately $1.0–$1.2 billion, mainly to support COVID-19-related production, and an effective tax rate of approximately 20.5%.
- Acquisition and financing: Danaher raised approximately $1.73 billion in a common-stock offering and $1.67 billion in Series B mandatory convertible preferred stock proceeds in 2020, in addition to issuing debt. Year-end debt was $21.2 billion; approximately $4.4 billion of additional borrowing capacity was available under the Five-Year Facility after commercial-paper support. The company reported covenant compliance.
- Significant one-time items: The required product-line divestiture generated a $455 million pretax gain ($305 million after tax, or $0.42 per diluted share). Danaher recorded a $26 million loss on early debt extinguishment. It also recorded $22 million of impairment charges on certain long-lived assets; no goodwill impairment was recorded.
- Tax uncertainty: Danish tax assessments relating to historical withholding tax totaled approximately $611 million including interest through year-end, before a January 2021 notice that significantly reduced interest amounts; the company was reviewing the revised calculations. Resolution remains uncertain and could adversely affect cash flow and the effective tax rate. The IRS settled its 2012–2015 self-insurance tax audit in 2020 without a material financial-statement impact, but later years remained subject to inquiry.
- Other contingencies and risks: Danaher reported a $194 million environmental reserve and approximately $724 million of guarantees, which it did not expect to have a material financial-statement effect if triggered. Key broader risks include COVID-19 demand and supply uncertainty, acquisition integration and increased indebtedness, regulation and product quality, cybersecurity and data privacy, competition, foreign exchange, and international tax matters.
- Controls and audit: The auditor issued an unqualified opinion on the consolidated financial statements and internal control. However, management and the auditor excluded Cytiva from the internal-control assessment; Cytiva represented 36% of year-end assets and 15% of 2020 revenue.
Most important facts for investors to verify
- How much of 2020 growth and margin performance is sustainable without Cytiva acquisition effects and pandemic-related demand; review management’s non-GAAP core-sales definitions and reconciliations.
- Cytiva’s integration, organic growth, expected returns, and the final purchase-price allocation, including the significant goodwill and intangible assets recorded.
- Debt maturities, refinancing access, interest costs, and the company’s capacity to fund investment and dividends while maintaining liquidity.
- The outcome and potential cash and earnings effects of Danish tax assessments, later IRS inquiries, and other uncertain tax positions.
- Progress in incorporating Cytiva’s controls into Danaher’s reporting-control framework and the company’s planned 2021 capital spending and conditional outlook.